This article first appeared on GuruFocus .
Release Date: July 22, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Dynavox Group AB ( TDVXF ) reported a solid year-on-year revenue growth of 16% in Q2 2026, adjusted for currency effects.
-
Operating profit more than doubled compared to the same quarter last year, with a 130% increase, reaching 105 million SEK.
-
The company successfully concluded the global rollout of its new ERP system for all main legal entities.
-
A new health economic study in the US showed that Dynavox's solutions significantly improve quality of life for people with disabilities and provide economic benefits to society.
-
Dynavox Group AB ( TDVXF ) continues to expand its market presence, completing the acquisition of its Italian reseller partner, Sr. Labs Healthcare.
Negative Points
-
Currency fluctuations had a negative impact of 5% on revenue.
-
The company experienced longer prescription processes, particularly in North America, leading to delays in revenue recognition.
-
There is a recurring complexity and bureaucracy in reimbursement processes, which remains a headwind.
-
Component costs have increased, partially offsetting the benefits from lower freight costs.
-
The company filed a lawsuit against AbleNet in the US, which could involve legal expenses and potential operational distractions.
Q & A Highlights
Q: Can you elaborate on the longer prescription processes and whether this trend will ease off or worsen? A: (Fredrik Rubin, CEO) The longer prescription processes are primarily observed in the US, particularly at the start of the year when people change insurance providers, often resulting in a change of therapists. This leads to increased lead times. While this trend is not new, it has been more pronounced this year. It's difficult to predict when this will taper off, but there is no fundamental change in the number of users or reimbursement policies.
Q: What are the costs associated with the AbleNet lawsuit, and will it significantly impact operating expenses? A: (Linda Tybring, CFO) The costs related to the AbleNet lawsuit are not substantial and will only be a small part of our operating expenses. It should not influence our long-term financial guidance.
Q: With net debt decreasing to 1.6 times rolling EBITDA, what are your thoughts on M&A activities? A: (Fredrik Rubin, CEO) Our growth strategy is largely organic, with M&A being a minor component. Historically, M&A has contributed low single-digit percentage points to our growth. Recent acquisitions, such as buying our own resellers, have a small financial impact since the difference is mainly between what we sold to the reseller and what they sold to the market.
Q: Can you comment on the impact of component cost increases, particularly from Apple, on your gross margin? A: (Linda Tybring, CFO) We expect a slight impact on the gross margin, slightly below one percentage point over the next 12 months, due to increased component costs, including those from Apple. However, we are also benefiting from reduced freight costs, which helps offset some of these increases.
Q: How do you address the issue of devices not being used as intended, particularly in the Swedish market? A: (Fredrik Rubin, CEO) The main reason devices are not used is not due to the technology but rather life circumstances and insufficient support infrastructure around the patient. This issue is universal and not unique to Sweden. The competence among those tasked with assisting users is often low, and we aim to improve this through education and support.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
